Latest Hyperphosphatemia News
A randomized controlled pilot study demonstrated the feasibility and safety of performing a large clinical trial that is powered to establish whether phosphate lowering reduces fatal and nonfatal cardiovascular events.
Each 1-mg/dL increase in serum phosphorus among kidney transplant recipients is associated with 36% and 21% increased risk in graft failure and death, respectively.
Phase 2 randomized placebo-controlled trial demonstrated the safety and efficacy of sevelamer in lowering serum phosphorus levels in children and adolescents.
Creatinine, phosphorus, and electrolyte levels were not significantly different for exposed and unexposed hospitalized patients.
New findings suggest that nutritional index should be considered in the management of phosphorus level in HD patients, researchers conclude.
Of 7 phosphate binders, iron-based agents were optimal when efficacy and safety are considered.
Almost 40% of pre-dialysis patients with stage 4-5 CKD patients and type 2 diabetes had lab results suggesting low turnover bone disease.
Serum phosphorus and intact parathyroid hormone levels were not reduced with 12 weeks of rilonacept therapy.
CKD patients with and without diastolic dysfunction had average serum phosphate levels of 7.3 and 5.5 mg/dL, respectively.
The proportion of patients with serum phosphorus levels within target range rose from 22% to 65% within 6 months of starting ferric citrate treatment.
Use of sevelamer was associated with a 14% decreased risk of death compared with non-use.
Among other changes, the new KDIGO guidelines highlight the potential dangers of hypercalcemia.
From 2003 to 2011 there was a 26.7% decrease in in-hospital mortality rate after hip fracture.
Patients receiving educational or behavioral interventions aimed at controlling hyperphosphatemia had an average reduction in phosphate of 0.23 mmol/L more than standard care patients.
Converting hemodialysis patient to sucroferric oxyhydroxide from a previous binder increased the proportion of patients achieving target serum phosphorus levels.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)